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Renewed interest in the kallikrein-kinin system was awak-
ened in the early seventies by the suggestion that it might be
involved in the regulation of sodium excretion [1, 2] or in the
development of hypertension [3, 4]. However, due to complex-
ities inherent in the measurement of the enzyme in the kidneys,
only a few reports on the activity of the renal kallikrein have
been published to date [5—8].
The analytical methods developed for the measurement of
urinary kallikrein [3, 9, 10] also have been used to measure the
kallikrein activity in the kidney homogenates. The estimation of
kallikrein by use of its capacity to hydrolyse synthetic esters of
arginine has the disadvantage of limited specificity. It has been
reported that up to 75% of the urinary esterase activity may be
unrelated to kallikrein [11]. This non-kinin generating esterase
is also present in the kidney [12]. The kininogenase method,
which relies on the release of kinins from kininogen [10],
appears to be more specific. However, to avoid the interference
of plasma kallikrein (a kininogenase produced by the liver [13])
the kidneys should be, as far as possible, free of blood.
Plasma kallikrein has a low affinity for a synthetic amide
substrate [14] recently developed for the measurement of
urinary kallikrein (4 x lO M plasma kallikrein will hydrolyse
4.6% of the amount hydrolysed by an equal concentration of
glandular kallikrein [15]). This suggests that plasma kallikrein
will not interfere with the renal kininogenase when assaying the
kidney homogenates with this substrate.
We tested the adequacy of the amidolytic assay to measure
renal kallikrein by comparing it to the kininogenase method. We
also investigated whether the arterial perfusion with isotonic
saline used to rinse the kidneys could be avoided when the renal
kallikrein activity was measured by the amidolytic assay. The
validity of this method to measure renal kallikrein was investi-
gated further by measuring the enzyme in the kidneys from rats
with normal, low (adrenalectomized) and high (sodium deplet-
ed) kallikrein activity. Additionally, two procedures for prepar-
ing the renal cortex homogenates were compared.
Methods. The amidolytic and the kininogenase activities of
renal homogenates were measured in: (I) Normal male rats of
the Wistar strain fed normal rat chow; (2) renal hypertensive
rats, in which high blood pressure was induced by ligature of
the aorta between the origin of the renal arteries; the kallikrein
activity was measured in both the ischemic and the contralater-
al kidney; (3) unilateral nephrectomized rats; the kallikrein
activity was measured in the remaining kidney I week after
nephrectomy; (4) rats fed a sodium deficient diet for 14 days;
their daily sodium excretion by the end of the experiment was
0.010 0.005 mmole Na1day.
Additionally, we measured the amidolytic activity in the renal
cortex of adrenalectomized rats which were fed a normal rat
chow and given 1% sodium chloride to drink. Kidneys were
obtained from anesthetized rats (pentobarbital: 60 mg/kg body
wt i.p. or diethylether). To minimize the interference of plasma
kallikrein, we perfused the kidneys by hydrostatic pressure (100
cm) with 150 mi,vi NaCI by a catheter advanced to the ascending
aorta through the left ventricle. The kidneys were either proc-
essed immediately or kept at —20°C.
The renal cortex was homogenized mechanically in tris/
hydrochloric acid buffer (0.1 M, pH 8.2) for 30 sec while keeping
the samples refrigerated (Polytron®, Kinematica, Kriens/Lu-
cern, Switzerland). To solubilize the membrane-bound kalli-
krein, the homogenates were brought to a dilution of 1:25 with
the tris/hydrochloric acid buffer and incubated for 20 mm at 4°C
in the presence of 0.4% sodium desoxycholate [16]. The homog-
enates were then brought to the final dilution with the same tris/
hydrochloric acid buffer and centrifuged at x 50,000g and 4°C
for 30 mm. The supernatant was used to measure the kininogen-
ase and the amidolytic activities.
Ultrasound was also used to solubilize renal kallikrein. Ten
milligrams of cortex in 900 d tris/hydrochloric acid buffer (0.1
M, pH 8.2) were sonicated (Sonifier® B-l2, Branson Sonnic
Power Co., Danbury, Connecticut) with the standard microtip
at 40% maximal energy and 20 kilohertz (kHz) for 10 sec, while
keeping the sample refrigerated. After 1 mm the sonication was
repeated. The samples were centrifuged (x24,000g, 4°C, 15
mm), and the amidolytic activity was measured in the
supernatant.
The kininogenase activity was measured by incubating appro-
priately diluted kidney homogenates with 5 mg/mI semipurified
dog kininogen prepared from plasma heated to 58 to 60°C for 3
hr by ammonium sulfate fractionation (20 to 40% saturation)
and lyophylized as previously described [17]. The kidney
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homogenates were incubated with this substrate at 37°C for 20
mm in tris/hydrochioric acid buffer (0.1 M, pH 8.2) containing o-
phenanthroline (3.5 mM), Na2-ethylene diaminotetraacetate (1
mM), neomycin (0.2 g/liter) and human serum albumin (0.5 g/
liter). The kinins released were measured by radio-immunoas-
say after stopping the reaction with 40 volumes of ethanol,
evaporation to dryness, and dissolution of the residue in 0.1 M
tris/hydrochioric acid buffer (pH 7.4) containing 1 g/liter gela-
tine and 1 gfliter neomycin [18]. The kallikrein activity was
calculated in micrograms of kinins released per minute of
incubation and grams of kidney (wet weight) or as nanograms of
kinins released per minute of incubation and milligrams of
protein. Synthetic bradykinin was used as the standard.
The amidolytic activity was measured by incubating appro-
priately diluted kidney homogenates (1:50 to 1:100) with 0.15
mM D-vai-leu-arg-paranitroanilide (S2266, Kabi Diagnostica, S-
11287 Stockholm, Sweden) in 1 ml tris/hydrochloric acid buffer
(0.1 M, pH 8.2). After incubation at 37°C for 120 mm, the
reaction was stopped by the addition of 100 d 50% acetic acid
followed by centrifugation (x24,000g, 15 mm) to discard the
precipitated proteins or by adding 2300 KIU aprotinin. To
assess the efficacy of aprotinin to stop the reaction the optical
density of a set of samples (N = 4) was measured immediately
after the addition of the inhibitor and every is mm thereafter
until 60 mm. The color developed during the incubation was
measured at 405 nm (Perkin-Elmer 550A, Oak Brook, Illinois)
against a blank which was identical with each sample except
that it contained, in addition, 500 KIU aprotinin/mi. With each
assay external standards containing 0.0125, 0.025, and 0.050
KU/mi hog pancreas kallikrein were run. In a group of normal
rats and in one of sodium-depleted rats the blanks were
prepared by adding the substrate after the reaction had been
stopped with acetic acid, thus avoiding the addition of apro-
tinin. The kallikrein activity measured with the amidolytic
assay was expressed in mU/g kidney (wet weight) or in mU/mg
protein. One unit was the amount of enzyme capable of splitting
I jtmole of substrate per minute. To assess procedural-related
losses of the enzyme, the amidolytic activity was not only
measured in the supernatant of homogenates (N = 4) prepared
with a blade homogenizer and containing desoxycholate as
described but also in the precipitates which were resuspended
in tris/hydrochloric acid buffer (0.1 M, pH 8.2), and then
incubated with D-val-leu-arg-paranitroanilide. The blanks con-
tained 500 KIU/mi aprotinin. After stopping the reaction by the
addition of acetic acid, the samples were centrifuged and their
optical density was measured. The activity of the resuspended
precipitate was calculated as percent of the total.
Additionally, the recovery of exogenously added kallikrein
was investigated. Hog pancreas kallikrein (1 KU/mi) was added
to homogenates prior to the addition of desoxycholate. The
optical density measured after incubation of the supernatants
containing hog kallikrein with D-val-leu-arg-paranitroanilide
was compared to that obtained after separate incubation of the
same amount of purified enzyme and of supernatant with the
substrate.
To assess whether or not plasma kallikrein interferes with the
assay, the amidolytic activity in renal cortex from saline-
perfused kidneys of normal rats was compared to that of the
contralateral organs, which were not perfused.
The adequacy of the amidolytic assay to measure kallikrein
activity was investigated further by incubating renal homoge-
nates from normal rats with D-val-leu-arg-paranitroanilide for
various time intervals. The reaction was stopped with 2300 KIU
aprotinin. The influence of the concentration of kallikrein on
the release of paranitroaniline was studied by incubating 0.25,
0.5, and 1.0 mg cortex (wet weight) per milliliter with the amide
substrate for 120 mm and stopping the reaction with 100 d
acetic acid.
The concentration of protein in the supernatant of cortex
homogenates was measured with the method of Lowry et al
[191.
Statistical analysis: Means and SEM were calculated by
standard procedures. The degree of correlation between the
amidolytic and the kininogenase assays was calculated by
regression analysis.
Results. In normal rats and in rats from various experimental
models a significant correlation between the amidolytic and
kininogenase activities of supernatants from renal cortex ho-
mogenates was observed (Fig. 1, Table 1). The intercept of the
regression line calculated with values from normal rats was,
within a 95% confidence limit, different from zero [a (t2
0.05) SDa 29.47 15.79].
Only 0.2% of the total amidolytic activity of renal cortex
homogenates remained in the precipitate.
A linear relationship between the concentration of hog pan-
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Fig. 1. Correlation between the release ofkinins from dog kininogen
(abscissa) and hydrolysis of D-val-leu-arg-paranitroanilide (ordinate)
by homogenates of normal rat kidneys. The full line represents the
regression for all values (N = 57, r = 0.74, P < 0.001) and has an
intercept which differs from zero (29.47 15.79).
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Experimental group Pairs
Coefficient of
correlation Significance
Normals 31 0.8234 P < 0.001
Renal hypertensives 12 0.9511 P<0.001
Uninephrectomized 10 0.7961 P < 0.01
Sodium-depleted 8 0.8436 P < 0.01
creas kallikrein and hydrolysis of the synthetic peptide was
found, The optical density obtained with this external standard
was 0.078 0.005, 0.165 0.010, and 0.338 0.009 when 12.5,
25, and 50 mKU/ml were incubated for 2 hr with the synthetic
substrate (r = 0.99, N = 78).
The release of paranitroaniline from D-val-leu-arg-parani-
troanilide by the renal homogenates was proportional to the
incubation time (Fig. 2) and also to the amount of renal tissue
used (Fig. 3).
The recovery of exogenous kallikrein was 97 3% (N = 4)
when the reaction was stopped with acetic acid and 95 5% (N
= 4) when it was stopped with aprotinin. This inhibitor effec-
tively stopped the reaction since the optical density of incubates
from normal renal cortex remained unchanged up to 60 mm
after its addition (rt 0 mm: 0.101 0.004, r 60 mm: 0.100
0.012, N = 4) and did not differ from that obtained 0, 15, 30, and
60 mm after the addition of acetic acid.
In normal rats, when both kidneys were perfused free of
blood and the cortex was homogenized mechanically, the
kallikrein activity of the right kidney (106 7 mU/g, N 9) was
not different from that of the contralateral (100 8, mU/g, N =
9).
No difference was observed between the amidolytic activity
of ultrasound homogenates from cortex of normal kidneys
which were perfused with saline and the activity of homoge-
nates from non-perfused kidneys (97 6 mU/g, N = 13; 92 6
mU/g, N = 13).
Also in sodium-depleted rats the cortical kallikrein activity
was not affected by saline perfusion (perfused kidneys: 240 18
mUIg, N = 8; non-perfused kidneys: 228 22 mUIg, N = 8).
Because perfusion reduced the protein concentration of the
renal cortex (173 4 vs. 216 5 mg/g wet weight), the
kallikrein activity per milligram of protein was higher in the
perfused kidney (1.38 0.09 mU/mg, N = 8) than in the non-
perfused (1.07 0.11, N = 8; P <0.05).
The amidolytic activity of the renal cortex from another
group of normal rats (not perfused) was 100 13 mU/g (N = 6)
when kallikrein was brought into solution by mechanical ho-
mogenization and the addition of desoxycholate and 101 8
mU/g (N = 6) in homogenates prepared by ultrasound. These
values do not differ significantly. The renal amidolytic activity
of sodium-depleted rats was 245 19 mU/g (N = 6) when
measured after mechanical homogenization plus desoxycholate
and 200 17 mU/g (N = 6) when measured in sonicated
samples. This difference is not significant.
When aprotinin was included in the blanks, the activity of
cortical kallikrein was 110 6 mU/g (N = 6) in saline-perfused
kidneys and 114 10 mU/g (N = 6) in non-perfused kidneys,
which did not differ from the activity obtained when aprotinin
was omitted (saline perfused kidneys: 113 4 mUIg, N = 6;
non-perfused: 97 9 mU/g, N = 6).
Discussion. We have shown previously the adequacy of the
amidolytic assay with D-val-leu-arg-paranitroanilide for the
estimation of urinary kallikrein [201. It can be inferred, from the
time and dilution curves of the amidolytic activity of renal
homogenates as well as from the correlations between the
amidolytic and kininogenase activities in different experimental
conditions, that D-val-leu-arg-paranitroanilide is also an ade-
quate substrate to estimate the renal kallikrein activity. Howev-
er, it is not possible to assure that kallikrein is the only renal
enzyme capable of splitting this synthetic tripeptide. The inter-
cept of the regression line calculated with the amidolytic and
kininogenase activities of normal kidneys at a point which
differs from zero suggests the presence of an amidase different
from kallikrein. But is also possible that the curve was shifted
by an underestimation of the kininogenase activity. One possi-
ble explanation could be that some kallikrein molecules are
bound to an inhibitor which prevents the binding of the enzyme
to kininogen but not to the small synthetic tripeptide. If this is
true, the amidolytic assay would more accurately reflect the
kallikrein activity. However, until it is ruled out that other
enzymes potentially capable to hydrolyse D-val-leu-arg-parani-
troanilide and kininogen (that is, trypsin, elastase, plasmin) are
present in the kidney, neither the amidolytic nor the kininogen-
ase methods should be viewed as specific assays for kallikrein.
For the measurement of renal kallikrein activity, the enzyme
Table 1. Correlations between the kininogenase and amidolytic
activities of rat renal cortex homogenates
0d
0 10 20 30 40
Incubation time, mm
Fig. 2. The effect of the time of incubation on the optical density at 405
nm (O.D.) after incubation of kidney homogenates (4 mg wet weight)
with 0.15 msi D-val-leu-arg-paranitroanilide (N = 7).
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Fig. 3. The effect of kidney homogenates (N = 7) on the optical density
at 405 nm (O.D.) after incubation with 0.15 mw D-val-leu-arg-parani-
troanilide for 120 mm at 37°C.
can be solubilized either by mechanical homogenization and the
addition of desoxycholate or by ultrasound. Due to the low
affinity of plasma kallikrein for D-val-leu-arg-paranitroanilide, it
is unnecessary to use blood-free kidney homogenates. The use
of aprotinin in the blank to exclude some amidolytic enzymes
unrelated to kallikrein (that is, urokinase, thrombin) does not
seem to be essential. The reaction can be stopped by adding
acetic acid or aprotinin.
The amidolytic method used to estimate the renal kallikrein
activity can be summarized as follows: Rat renal cortex (10 mg)
was suspended in 900 1.d tris/hydrochloric acid buffer (0.1 M, pH
8.2) and sonicated twice for 10 sec while keeping the sample
refrigerated. Alternatively, renal cortex was homogenized me-
chanically in tris/hydrochioric acid buffer followed by desoxy-
cholate (0.4%, wlv) addition. After centrifugation, 100 sl of the
supernatant (containing 10 to 20 mg cortex per milliliter) were
incubated in 1 ml tris/hydrochloric acid buffer with 0.15 mvi D-
val-leu-arg-paranitroanilide for 120 mm at 37°C. The reaction
was stopped by adding 100 .d 50% acetic acid or 2300 KIU
aprotinin. A blank was prepared for each sample by adding 500
KIU aprotinin to the incubation mixture or by adding acetic
acid and substrate at the end of the 120 mm of incubation. After
centrifugation, the amidolytic activity of the renal cortex was
calculated from the optical density obtained at 405 nm [RKa1
(mUIg) = 8.73 x E x cortex dilution].
Table 2. Amidolytic activity in cortical homogenates of nonperfused
kidneys from normal, adrenalectomized, and sodium-depleted rats
Experimental
group Kidney, mUig Protein, mU/mg
Normal rats 101 8 (N 7) 0.47 0.05 (N = 7)
Adrenalectomized 51 9a (N 12) 0.27 0.05a (N = 12)
Sodium-depleted 200 17a (N 6) 0.74 0.07a (N = 7)
Value differs from normal rats with P < 0.001.
The amidolytic (kallikrein) activity of the renal cortex of
normal rats was about 100 mU/g wet weight when calculated on
the basis of the amount of substrate hydrolysed and 2 KU/g wet
weight when calculated on the basis of the amidolytic activity of
an external standard. The kallikrein activity of the renal cortex
was higher than normal in salt-depleted rats and lower than
normal in adrenalectomized rats (Table 2).
With the method described, the necessity for expensive
equipment (gamma or beta counter) as well as the use of
radioactive tracers is avoided. Although the technical advan-
tage of the amidolytic method over previously reported proce-
dures is obvious, the possibility that the specificity of the assay
may be tempered by the appearance of amidases different from
kallikrein in pathological conditions should be kept in mind. For
the specific measurement of renal kallikrein, it may be appropri-
ate to combine the amidolytic assay with the use of a specific
inhibitor of kallikrein, like the Fab fragments from antibodies
directed against the active center of the enzyme [21],
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